30 aug. 2016 — Betagenon AB/Baltic Bio AB startar Fas 2a "proof-of-concept" klinisk prövning av AMPK aktivator O304 i Typ 2 Diabetiker. Avslut av Fas 1 och

Betagenon AB/Baltic Bio AB announces the initiation of Phase I clinical studies with O304, an orally available AMPK activator. March 10, 2014 10:47 AM Eastern Daylight Time. STOCKHOLM

Betagenon is a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Betagenon Sweden AB c/o BETAGENON SWEDEN AB VÄSTRA STRANDGATAN 9 B 903 26 Umeå Visa fler bolag på denna adress Anmärkningskontroll Kreditupplysning med viktig information: Ingen anmärkning, ansökan, skuldsaldo, utmätning eller konkursbeslut registrerat. Kontrollerat 2021-04-02 Bolagsinformation Betagenon /Balticgruppen Bio AB announces the start of a bridging PK and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator compound O304. Licence agreementCancer drug developer Antisoma and Betagenon, a privately held Swedish biotechnology company, have announced that Antisoma has licensed rights to develop and commercialise Betagenon’s AMPK (AMP activated protein kinase) activators in cancer indications. Terms were not disclosed.

Betagenon AB operates as a biotechnology company. The Company develops novel, safe, and effective therapies for treatment of obesity-related disorders including type 2 diabetes, fatty liver Betagenon/Baltic Bio announces positive results from a 28 day Phase IIa trial of the first-in-class AMPK activator. The main study results are not yet finalized but review of the initial data showed that a number of patients who were included based on HbA1c at screening, had FPG below 7 mM or above 13.3 mM at day 1, and that the data analysis of FPG required a post hoc analysis plan, according to the company. Betagenon has successfully taken its first-in-class PAN-AMPK-activator O304, a novel small molecule for treatment of cardio-metabolic disorders, through pre-clinical and clinical Phase I and Phase IIa testing as well as long-term toxicological studies in animals. The results show that beneficial cardiovascular and metabolic effects Betagenon AB/Baltic Bio AB startar Fas 2a "proof-of-concept" klinisk prövning av AMPK aktivator O304 i Typ 2 Diabetiker. Avslut av Fas 1 och start av Fas 2a klinisk prövning av O304. Ett säkert dos-intervall av O304 för fortsatta kliniska studi Betagenon’s offices are currently situated in Uminova Science Park, and although the company has not been enrolled in the business coaching services, they have utilized equipment and facilities across the hall at UBI, as in Umeå Biotech Incubator.

Styrelsesuppleant, Gabather Finans AB. Styrelseledamot, Genagon Therapeutics AB. Styrelseledamot, Arild Capital AB. Styrelseledamot, Betagenon Bio AB

Privately funded Betagenon has partnered up with Baltic Bio to share the profits from a type 2 diabetes candidate, 0304. Betagenon has identified an enzyme activator that is intended as a drug candidate for multiple lifestyle and age disorders such as diabetes and heart failure. Ivy Capital is now investing SEK 28.5 million into Betagenon to help support clinical development of the drug. Betagenon AB is a privately owned Swedish Biotechnology company, and Baltic Bio AB is a subsidiary of the investment company Fort Knox Forvaring AB, Umea, Sweden.

Betagenon Sweden AB - Org.nummer: 5566158712. Vid senaste bokslut 2019 hade företaget en omsättningsförändring på -78,2%. Ansvarig är Nils Erik Martin Gunhaga 45 år. På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat.

Alltid uppdaterat.

Betagenon AB has received funding from the EU’s research and innovation framework programme … Betagenon Sweden AB - Org.nummer: 5566158712. Vid senaste bokslut 2019 hade företaget en omsättningsförändring på -78,2%. Ansvarig är Nils Erik Martin Gunhaga 45 år. På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat. Betagenon is a biopharmaceutical company based in Sweden. Betagenon is a biotechnology company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals.
Månadskostnad boendeparkering stockholm

A few weeks ago, Betagenon launched their Phase II clinical trial that will be performed in Stockholm and Uppsala. In total, 66 patients with type-2 diabetes will be given a candidate drug to access the pharmacological effects on one of the world most wide spread diseases. Around 400 million people globally are diagnosed with type-2 […] BioStock Studio: Aegirbio om affären med LifeAssays och Abreos Biosciences.

2020 — Det kinesiska investmentbolaget Ivy Capital investerar nu närmare 30 miljoner kronor i Umeåbaserade Betagenon. Helena och Thomas Edlund Den pågående kliniska prövningen av läkemedelskandidaten AMPK aktivator O304 sker genom Umeåforskarnas avknoppningsföretag Betagenon AB. Nyheter. Artiklar om Betagenon (2); 2008; februari (2).
Vintergalan 2021 show, 1 december

Betagenon/Baltic Bio Announces Positive Results From a 28-day Phase IIa Trial of the First-in-class AMPK Activator O304 in Type 2 Diabetics - read this article along with other careers information, tips and advice on BioSpace

Ivy Capital is now investing SEK 28.5 million into Betagenon to help support clinical development of the drug. Betagenon develops therapies for chronic energy balance disorders and has received funding from the EU’s program for research and innovation, Horizon 2020.